Cargando…
Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations
Testing for the CALR mutation is included in the updated WHO criteria for essential thrombocythaemia (ET) and primary myelofibrosis (PMF). We report on the application of the CAL2 monoclonal antibody, raised against the mutated CALR gene to myeloid cases. The immunostain was used on 116 acute myeloi...
Autores principales: | Ali, Hebah, Puccio, Ignazio, Akarca, Ayse U., Bob, Roshanak, Pomplun, Sabine, Keong Wong, Wai, Gupta, Rajeev, Sekhar, Mallika, Lambert, Jonathan, Al‐Masri, Hytham, Stein, Harald, Marafioti, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839955/ https://www.ncbi.nlm.nih.gov/pubmed/32929772 http://dx.doi.org/10.1111/iep.12375 |
Ejemplares similares
-
Differential response of early erythropoietic and granulopoietic progenitors to dexamethasone and cortisone
Publicado: (1979) -
CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016) -
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021) -
CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020) -
Design of novel granulopoietic proteins by topological rescaffolding
por: Hernandez Alvarez, Birte, et al.
Publicado: (2020)